The news of JMP Securities maintaining a Market Outperform rating on Cormedix and raising the price target from $16 to $19 is positive for the stock. This indicates that the analyst believes the stock will outperform the market and has increased confidence in its potential upside. This is likely to have a positive impact on the stock price in the short term.